

Protect Your Baby Against Severe RSV with the Maternal Vaccine (Abrysvo)


November 2025

Respiratory syncytial virus (RSV) is a common virus that affects the lungs. It can be very dangerous for babies and older adults, and it's the leading cause of hospitalization in babies. Fortunately, there are options to protect babies from severe RSV and most only need one: a maternal vaccine given once during pregnancy or the RSV antibody given to the baby.

If you need help accessing or understanding this information, contact ahs.vdhimmunizationprogram@vermont.gov

Abrysvo is about 70% effective at preventing babies from being hospitalized with RSV.¹

RSV Facts



- RSV season starts in the fall and peaks in winter.
- It can spread when an infected person coughs or sneezes, by direct contact with someone who has RSV, or from contaminated surfaces.
- Many adults with RSV do not have any symptoms. Those who do will usually have a mild, cold-like illness.
- Very young infants with RSV almost always show symptoms. These include irritability, decreased activity, drinking or eating less, and apnea (pauses in breathing for more than 10 seconds).
- RSV can cause severe illness in infants and young children such as bronchitis (inflammation of the small airways in the lungs) or pneumonia (infection of the lungs).

Maternal Vaccine (Abrysvo) Recommendations



- The maternal RSV vaccine is recommended if you are 32-36 weeks pregnant between September and January. If you already got the RSV vaccine during a past pregnancy, you don't need it again. Instead, your new baby should receive the antibody option.
- The vaccine is given as a single shot. Side effects are usually mild and may include headache, nausea, and a sore arm.
- The vaccine helps your body make protection (antibodies) that you pass on to your baby. Protection takes about two weeks to develop and lasts through your baby's first six months, when they are most at risk.

¹Alandijany, T. A., & Qashqari, F.S. (2025). Evaluating the efficacy, safety, and immunogenicity of FDA-approved RSV vaccines: A systematic review of Arexvy, Abrysvo, and mResvia. *Frontiers in Immunology*, 16. <https://doi.org/10.3389/fimmu.2025.1624007>



HealthVermont.gov/RSV
802-863-7200

